Oops, an error occurred! Code: 202602052208336c3c240d

Targeted Metabolomics

We develop improved diagnostic tests for conditions related to metabolic dysfunction, including chronic kidney, liver, and cardiac diseases.

NMR Metabolomics

From a single serum sample, we quantify multiple biomarkers—both known and newly discovered. Precision diagnostics.

AXINON® System

Using FDA-cleared technology, this is our core platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy. It's the first modular software-based system for clinical diagnostics. 

Precision Diagnostics

AXINON® System, Using FDA-Cleared Technology

 

Numares Health develops advanced biomarker tests to diagnose and measure disease progression for conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. 

We use nuclear magnetic resonance (NMR) spectroscopy to quantify multiple biomarkers — known and newly discovered — from a single serum sample. Machine learning then identifies the few, specific metabolitesrelevant to diagnosis.

The AXINON® System, using FDA-cleared technology, is our core technology platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.

Disrupting Diagnostics

  • The FDA-cleared AXINON® LDL-p Test System, is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

  • AXINON® lipoFIT® is a cardiovascular risk assessment, available as a CE-labeled in vitro diagnostic product in the EU.  

Personalized Assessment Using Multiplex Metabolomics

Cardiology

AXINON® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.

AXINON® lipoFIT®: For cardiovascular risk assessment. 

Available as a CE-labled in vitro diagnostic product in the EU

Nephrology

AXINON® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy. 

Available as a CE-labled in vitro diagnostic product in the EU

Hepatology

AXINON® HCC(NMR): Liver risk assessment and cancer early detection test.

In development

Press Releases

numares Health enters ASEAN region with regulatory approval in Malaysia and…

European Investment Bank Finances Innovative Diagnostics Developer Numares…

numares Health and Mayo Clinic Strengthening Collaboration for Improved…

Social Media

Numares Health and Mayo Clinic Strengthening Collaboration for Improved…

 

Kidney Week 2022

Join us Nov. 3-6 at exhibit booth #2533 during ASN Kidney…

Physicians who treat CDK patients: Join us in Orlando Thursday, Nov. 3,…

 

You did not activate the necessary cookies for this content.

activate necessary cookies and show content